{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:27:00Z","timestamp":1788791220332,"version":"build-2803163510"},"reference-count":11,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.annder.2020.08.053","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T20:06:01Z","timestamp":1611000361000},"page":"60-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Refractory bullous pemphigoid with IgE anti-BP230 and IgG anti-p200 antibodies successfully treated with omalizumab"],"prefix":"10.1016","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-6937","authenticated-orcid":false,"given":"M.","family":"Sarrazin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Jouen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Duvert-Lehembre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2020.08.053_bib0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clim.2018.12.015","article-title":"IgE blockade in autoimmunity: omalizumab induced remission of bullous pemphigoid","volume":"198","author":"James","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1016\/j.annder.2020.08.053_bib0065","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jim.2009.04.013","article-title":"A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid","volume":"346","author":"Messingham","year":"2009","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.annder.2020.08.053_bib0070","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1038\/sj.jid.5700958","article-title":"A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu\/nu mice","volume":"127","author":"Fairley","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2020.08.053_bib0075","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.2147\/DDDT.S56004","article-title":"Profile of omalizumab in the treatment of chronic spontaneous urticaria","volume":"9","author":"Labrador-Horrillo","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.annder.2020.08.053_bib0080","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature","volume":"20","author":"Kremer","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.annder.2020.08.053_bib0085","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2020.08.053_bib0090","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.3389\/fimmu.2019.01919","article-title":"Effects of omalizumab on Fc\u025bRI and IgE expression in lesional skin of bullous pemphigoid","volume":"10","author":"Seyed Jafari","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.annder.2020.08.053_bib0095","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12026-014-8547-7","article-title":"Unravelling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid","volume":"59","author":"Messingham","year":"2014","journal-title":"Immunol Res"},{"key":"10.1016\/j.annder.2020.08.053_bib0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archdermatol.2007.9","article-title":"Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid","volume":"144","author":"Iwata","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2020.08.053_bib0105","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3389\/fimmu.2019.02466","article-title":"Anti-p200 pemphigoid: a systematic review","volume":"10","author":"Kridin","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.annder.2020.08.053_bib0110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjd.15114","article-title":"Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid","volume":"177","author":"Hashimoto","year":"2017","journal-title":"Br J Dermatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S015196382031156X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S015196382031156X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:09:51Z","timestamp":1758971391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S015196382031156X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S015196382031156X"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2020.08.053","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refractory bullous pemphigoid with IgE anti-BP230 and IgG anti-p200 antibodies successfully treated with omalizumab","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2020.08.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}